IMM-101

IMM-101 is a heat-killed Mycobacterium obuense that is used as an immunotherapy in the treatment of various cancers. It is developed by Immodulon Therapeutics, a biopharmaceutical company specializing in immunotherapies.

Mechanism of Action

IMM-101 works by stimulating the immune system to recognize and attack cancer cells. It does this by activating dendritic cells, which are a type of immune cell that presents antigens to T cells. This results in the activation of both the innate and adaptive immune responses, leading to the destruction of cancer cells.

Clinical Trials

Several clinical trials have been conducted to evaluate the safety and efficacy of IMM-101. These trials have shown that IMM-101 is well-tolerated and can improve survival in patients with advanced melanoma and pancreatic cancer.

Side Effects

The most common side effects of IMM-101 are mild and include fever, fatigue, and injection site reactions. Serious side effects are rare but can include severe allergic reactions.

Future Research

Future research on IMM-101 is focused on evaluating its efficacy in combination with other treatments, such as chemotherapy and other immunotherapies. There is also interest in exploring its potential use in other types of cancer.

See Also

• Immunotherapy
• Cancer
• Clinical trial
• Mycobacterium obuense
• Immodulon Therapeutics